Skip to content

Impact of Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent

Impact of Oral Iron Supplementation With Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent - A Non-Inferiority Safety Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00530374
Enrollment
268
Registered
2007-09-17
Start date
2007-11-30
Completion date
2009-04-30
Last updated
2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency, Malnutrition

Keywords

Pediatrics, Malnutrition, Iron Deficiency, Sprinkles, Oral Iron Supplementation

Brief summary

The purpose of this study is to determine the safety profile of oral iron supplementation (OIS) with Sprinkles in a pediatric population with high prevalence of Iron deficiency (ID) and moderate or severe malnutrition (MSM); the efficacy profile will also be investigated.

Detailed description

Iron deficiency (ID) affects many children in developing countries. Anemia and impaired brain development are its most significant consequences. These may be prevented by giving oral iron supplements (OIS), such as Sprinkles. ID treatment was controversial because high dose parenteral iron therapy is strongly associated with severe infections when given to severely malnourished children. Many studies have since demonstrated the safety of low dose OIS. WHO guidelines reflect this finding: population-wide iron supplementation campaign (PWISC), without prior screening, is recommended when ID prevalence is ≥ 40%. However, a gap in the safety evidence has been identified: children with moderate or severe malnutrition (MSM) are strikingly absent from the studies performed to date to investigate the link between OIS and infectious morbidities. In this context, PWISC may have unrecognized deleterious effects when the prevalence of MSM is high, since safety is assumed, but incorrectly extrapolated from available evidence. We wish to emphasize an additional concern with regards to safety studies published thus far: all were designed as superiority trials. In this context, it is statistically incorrect to conclude that failure to show a significant difference between iron and placebo means that their respective side-effect profiles are similar.

Interventions

DIETARY_SUPPLEMENTOral Iron Supplement

Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days

DIETARY_SUPPLEMENTPlacebo

Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days

Sponsors

Bangladesh Rural Advancement Committee
CollaboratorOTHER
International Centre for Diarrhoeal Disease Research, Bangladesh
CollaboratorOTHER
The Hospital for Sick Children
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Years to 2 Years
Healthy volunteers
No

Inclusion criteria

* children aged 12 - 24 months * moderate to severe malnutrition (MSM), defined as weight-for-age Z-score ≤ -2 based on the National Center for Health Statistics (NCHS) standards

Exclusion criteria

* severe anemia (hemoglobin ≤70g/L) * near normal hemoglobin concentration (\>100g/L) * weight-for-height \<-3 z-score (severe wasting) * kwashiorkor (defined as evidence of edema) * congenital abnormality or disease * treatment with iron supplements in the past 3 months * inclusion in a nutrition program in the past * chronic illness other than malnutrition.

Design outcomes

Primary

MeasureTime frame
A composite score based on the sum of all distinct episodes of diarrhea, dysentery and lower respiratory tract infections2 distinct and consecutive phases of 6 months each

Secondary

MeasureTime frame
Incidence of death and fever without a source [Safety]2 distinct and consecutive phases of 6 months each
Change in haemoglobin concentration after Sprinkles supplementation [Efficacy]2 distinct and consecutive phases of 6 months each

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026